Exelixis, Inc. (NASDAQ:EXEL) Shares Acquired by Principal Securities Inc.

Principal Securities Inc. increased its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 62.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 967 shares of the biotechnology company’s stock after buying an additional 373 shares during the quarter. Principal Securities Inc.’s holdings in Exelixis were worth $32,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of EXEL. Raymond James & Associates boosted its holdings in Exelixis by 118.2% during the third quarter. Raymond James & Associates now owns 239,661 shares of the biotechnology company’s stock worth $6,219,000 after buying an additional 129,805 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Exelixis by 18.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,317 shares of the biotechnology company’s stock valued at $268,000 after purchasing an additional 1,620 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in Exelixis by 4.6% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 143,547 shares of the biotechnology company’s stock valued at $3,725,000 after acquiring an additional 6,355 shares in the last quarter. Pallas Capital Advisors LLC purchased a new stake in Exelixis during the 3rd quarter worth $246,000. Finally, New York State Teachers Retirement System increased its position in shares of Exelixis by 4.8% during the third quarter. New York State Teachers Retirement System now owns 439,222 shares of the biotechnology company’s stock worth $11,398,000 after acquiring an additional 20,008 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Exelixis

In other news, Director Jack L. Wyszomierski sold 8,768 shares of the business’s stock in a transaction on Friday, February 28th. The shares were sold at an average price of $37.80, for a total transaction of $331,430.40. Following the transaction, the director now directly owns 356,605 shares in the company, valued at $13,479,669. The trade was a 2.40 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Patrick J. Haley sold 52,636 shares of the company’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the completion of the transaction, the executive vice president now directly owns 303,310 shares in the company, valued at $11,216,403.80. This trade represents a 14.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 130,343 shares of company stock valued at $4,789,234 in the last three months. 2.85% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. JMP Securities reiterated a “market outperform” rating and issued a $41.00 price target on shares of Exelixis in a research note on Thursday, January 23rd. Wells Fargo & Company cut shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $36.00 target price on the stock. in a report on Monday, February 24th. UBS Group raised their price target on shares of Exelixis from $30.00 to $34.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. Barclays boosted their price objective on shares of Exelixis from $25.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, February 13th. Finally, Stephens reissued an “equal weight” rating and issued a $29.00 target price on shares of Exelixis in a report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $37.24.

Exelixis Price Performance

Shares of Exelixis stock opened at $38.69 on Friday. The company has a market capitalization of $10.83 billion, a P/E ratio of 21.86, a PEG ratio of 1.13 and a beta of 0.53. The business’s fifty day moving average price is $34.53 and its two-hundred day moving average price is $31.62. Exelixis, Inc. has a 1-year low of $20.14 and a 1-year high of $38.72.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, research analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.